Registration Dossier

Toxicological information

Carcinogenicity

Currently viewing:

Administrative data

Description of key information

Key value for chemical safety assessment

Carcinogenicity: via oral route

Endpoint conclusion
Endpoint conclusion:
no study available

Carcinogenicity: via inhalation route

Endpoint conclusion
Endpoint conclusion:
no study available

Carcinogenicity: via dermal route

Endpoint conclusion
Endpoint conclusion:
no study available

Additional information

According to Regulation (EC) No. 1907/2006, Annex X, article 8.9.1, column 2, testing of carcinogenicity is not indicated, as several studies investigating the genetic toxicity of alkyl polyglycosides (APG) in-vitro and in-vivo have shown that APGs are not genotoxic. Moreover, the repeated dose toxicity test via the oral route conducted with D-Glucopyranose, oligomeric, C10-16-alkyl glycosides revealed no substance-related adverse effects indicative for carcinogenicity such as hyperplasia or pre-neoplastic changes (e. g. metaplasia).


Justification for selection of carcinogenicity via oral route endpoint:
No carcinogencity study is required, since the substance is not mutagenic and no hyperplasia or pre-neoplastic lesions were observed in any of the available studies.

Justification for selection of carcinogenicity via inhalation route endpoint:
No carcinogencity study is required, since the substance is not mutagenic and no hyperplasia or pre-neoplastic lesions were observed in any of the available studies.

Justification for selection of carcinogenicity via dermal route endpoint:
No carcinogencity study is required, since the substance is not mutagenic and no hyperplasia or pre-neoplastic lesions were observed in any of the available studies.

Justification for classification or non-classification